Skip to Main Content

04.17.18

A New Hepatitis C Treatment Costing $300 has 97 Percent Cure Rate

By | Leave a Comment

The non-profit research team Drugs for Neglected Diseases Initiative (DNDI) announced that after a 12-week Clinical Trial conducted in Malaysia and Thailand involving new drug candidate ravidasvir and existing drug sofosbuvir showed that ravidasvir/sofosbuvir combination to be safe and effective with an extremely high cure rate.

The treatment is produced by Egyptian drug manufacturer Pharco Pharmaceuticals and costs approximately $3.50 a day. Both DNDI and Pharco hopes that this will provide a viable alternative to those who cannot afford the treatment.

For more information: see: https://www.msn.com/en-us/health/medical/24300-hepatitis-c-treatment-has-97-percent-cure-rate/ar-AAvO2xe and https://www.sciencedaily.com/releases/2018/04/180412085720.htm

Comments are closed.

The views reflected in this blog are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.

See the full disclaimer and terms of use.